5:38 PM
Feb 28, 2019
 |  BC Week In Review  |  Company News  |  Deals

Abpro, NJCTTQ to develop bispecific antibodies in immuno-oncology

Antibody company Abpro Corp. (Woburn, Mass.) has partnered with Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (NJCTTQ) to use Abpro’s DiversImmune antibody discovery platform to develop multiple bispecific antibodies, including T cell engagers, to treat...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >